NCT02421185View on ClinicalTrials.gov

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

May 25, 2015

Primary Completion Date

May 13, 2019

Study Completion Date

May 16, 2019

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

JNJ-42756493 (erdafitinib)

"Part 1: Participants will receive 8 mg tablet once daily from Day 1 to 7, and then Day 15 to 21 of 28 days cycle or 8 mg orally once daily of 28 days cycle up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.~Part 2: Recommended Phase 2 JNJ-42756493 (erdafitinib) dose determined in Part 1."

Trial Locations (10)

Unknown

Changchun

Guangzhou

Hangzhou

Harbin

Nanjing

Shanghai

Seoul

Kaohsiung City

Tainan City

Taipei

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02421185 - Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter